chloroquine and derivatives - versus potential COVID-19 treatments - for COVID-19 prophylaxis pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.70 [0.24, 2.05]< 10%2 studies (2/-)74.4 %some concernnot evaluable moderatecrucial-
conversion to SARS-CoV- 2–positive status via NP swab 1.10 [0.76, 1.57]< 10%4 studies (4/-)31.0 %some concernnot evaluable moderateimportant-
hospitalization 0.98 [0.06, 15.77]< 10%1 study (1/-)50.5 %lownot evaluable highimportant-
laboratory-confirmed Covid-19 1.01 [0.76, 1.35]< 10%5 studies (5/-)46.4 %some concernnot evaluable moderateimportant-
new illness compatible with Covid-19 0.79 [0.63, 1.00]< 10%4 studies (4/-)97.3 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 0.91 [0.47, 1.77]< 10%2 studies (2/-)61.0 %some concernnot evaluable moderateimportant-
adverse events 2.64 [0.72, 9.63]< 199%5 studies (5/-)7.1 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.